Department of Cancer Therapy and Research, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Eur J Immunol. 2010 Jan;40(1):197-203. doi: 10.1002/eji.200939887.
CD25+ FOXP3+CD4+ T cells (Treg) have been considered to play an important role in immune tolerance against several tumor antigens. It has also been indicated that high-level expression of FOXP3 (FOXP3high) is sufficient to confer suppressive activity to normal non-Treg. Here, we showed for the first time that vascular endothelial growth factor receptor 2 (VEGFR2) is selectively expressed by FOXP3high but not FOXP3low Treg. Such VEGFR2+ Treg exist in several tissues including PBMC and malignant effusion-derived lymphocytes. In conclusion, VEGFR2 may be a novel target for controlling Treg with highly suppressive function.
CD25+ FOXP3+CD4+ T 细胞（Treg）被认为在针对多种肿瘤抗原的免疫耐受中发挥重要作用。也有研究表明，FOXP3 的高表达（FOXP3high）足以赋予正常非 Treg 抑制活性。在这里，我们首次表明，血管内皮生长因子受体 2（VEGFR2）选择性地表现在 FOXP3high 但不是 FOXP3low Treg 上。这种 VEGFR2+Treg 存在于包括 PBMC 和恶性渗出液来源的淋巴细胞在内的几种组织中。总之，VEGFR2 可能是控制具有高度抑制功能的 Treg 的新靶点。
